JPWO2019211310A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019211310A5 JPWO2019211310A5 JP2021510533A JP2021510533A JPWO2019211310A5 JP WO2019211310 A5 JPWO2019211310 A5 JP WO2019211310A5 JP 2021510533 A JP2021510533 A JP 2021510533A JP 2021510533 A JP2021510533 A JP 2021510533A JP WO2019211310 A5 JPWO2019211310 A5 JP WO2019211310A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- patient
- cells
- cell
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 62
- 239000003443 antiviral agent Substances 0.000 claims description 58
- 210000000822 natural killer cell Anatomy 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 238000002659 cell therapy Methods 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 27
- 230000007420 reactivation Effects 0.000 claims description 14
- 241001529453 unidentified herpesvirus Species 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000003211 malignant effect Effects 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 208000007514 Herpes zoster Diseases 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 238000011476 stem cell transplantation Methods 0.000 claims description 4
- 241000175212 Herpesvirales Species 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- -1 carrier Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229960004396 famciclovir Drugs 0.000 claims description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 229960001179 penciclovir Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229940093257 valacyclovir Drugs 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 35
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1807050.8 | 2018-04-30 | ||
| GBGB1807050.8A GB201807050D0 (en) | 2018-04-30 | 2018-04-30 | Medical uses |
| PCT/EP2019/061122 WO2019211310A1 (en) | 2018-04-30 | 2019-04-30 | Medical uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522914A JP2022522914A (ja) | 2022-04-21 |
| JPWO2019211310A5 true JPWO2019211310A5 (https=) | 2022-05-12 |
| JP2022522914A5 JP2022522914A5 (https=) | 2022-05-12 |
Family
ID=62494975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510533A Pending JP2022522914A (ja) | 2018-04-30 | 2019-04-30 | 医学的使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210186977A1 (https=) |
| EP (1) | EP3787685A1 (https=) |
| JP (1) | JP2022522914A (https=) |
| KR (1) | KR102908831B1 (https=) |
| CN (1) | CN112399858A (https=) |
| AU (1) | AU2019264457B2 (https=) |
| BR (1) | BR112020022062A2 (https=) |
| CA (1) | CA3097379A1 (https=) |
| GB (1) | GB201807050D0 (https=) |
| WO (1) | WO2019211310A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112168829B (zh) * | 2020-09-24 | 2022-02-15 | 华南理工大学 | 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007016450A2 (en) * | 2005-07-29 | 2007-02-08 | Beth Israel Deaconess Medical Center | Methods for treating or preventing reactivation of a latent herpesvirus infection |
| CN101506154B (zh) * | 2006-08-21 | 2015-06-17 | 辛塔制药公司 | 用于治疗增生性疾病的化合物 |
| US20090123442A1 (en) * | 2007-11-09 | 2009-05-14 | Avaris Ab | Expanded nk cells |
| US8877182B2 (en) * | 2009-03-26 | 2014-11-04 | Cellprotect Nordic Pharmaceuticals Ab | Expansion of NK cells |
| US20130011376A1 (en) * | 2009-12-29 | 2013-01-10 | Gamida Cell Ltd. | Methods for Enhancing Natural Killer Cell Proliferation and Activity |
| JP5989016B2 (ja) * | 2011-06-24 | 2016-09-07 | 国立大学法人九州大学 | Ｎｋ細胞の増幅方法 |
| JP6501264B2 (ja) * | 2012-07-24 | 2019-04-17 | アヴァリン ファーマ インク． | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 |
| US20180021378A1 (en) * | 2014-12-31 | 2018-01-25 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
| KR102416781B1 (ko) * | 2015-08-20 | 2022-07-05 | 고려대학교 산학협력단 | 수두 대상포진 바이러스에 의해 유발되는 질병의 치료 또는 예방용 약학 조성물 |
-
2018
- 2018-04-30 GB GBGB1807050.8A patent/GB201807050D0/en not_active Ceased
-
2019
- 2019-04-30 CN CN201980029357.3A patent/CN112399858A/zh active Pending
- 2019-04-30 KR KR1020207034431A patent/KR102908831B1/ko active Active
- 2019-04-30 US US17/048,702 patent/US20210186977A1/en active Pending
- 2019-04-30 BR BR112020022062-0A patent/BR112020022062A2/pt unknown
- 2019-04-30 EP EP19722058.5A patent/EP3787685A1/en active Pending
- 2019-04-30 AU AU2019264457A patent/AU2019264457B2/en active Active
- 2019-04-30 JP JP2021510533A patent/JP2022522914A/ja active Pending
- 2019-04-30 CA CA3097379A patent/CA3097379A1/en active Pending
- 2019-04-30 WO PCT/EP2019/061122 patent/WO2019211310A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3140021B2 (ja) | Ｔｎｆ阻害剤含有医薬組成物 | |
| AU2006320162B2 (en) | Use of high-dose oxazaphosphorine drugs for treating immune disorders | |
| JP3717950B2 (ja) | 免疫強化剤及び生理学的に許容され得るその塩 | |
| ES2981241T3 (es) | Formas cristalinas de tenofovir alafenamida | |
| TW202014193A (zh) | 包含碳環核苷酸之2’3’－環二核苷酸 | |
| EP3956329B9 (en) | Solid forms of a toll-like receptor modulator | |
| EP3956328B1 (en) | Solid forms of a toll-like receptor modulator | |
| JPWO2019211310A5 (https=) | ||
| JP2004035546A (ja) | サイトカインが関係する疾患治療法 | |
| Mueller et al. | Clinical Trials in Rheumatology | |
| JP2022522914A5 (https=) | ||
| KR960704464A (ko) | 포유동물 세포에서의 뉴클레오사이드와 뉴클레오베이스 수송억제 방법 및 바이러스 복제억제 방법(method for inhibiting nucleoside and nucleoside transport and virus replication in mammalian cells) | |
| AU2483300A (en) | Modulation of immune response by ribavirin | |
| WO1990006671A2 (en) | Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections | |
| TW202120092A (zh) | 化合物用於預防或治療移植物抗宿主病的用途 | |
| WO2021009333A1 (en) | Synergistic effect of eyp001 and ifn for the treatment of hbv infection | |
| US6107303A (en) | Treatment of Epstein Barr infection | |
| EP0522001B1 (en) | Supportive use of linomide (r) | |
| Khaidarov et al. | PHARMACOLOGICAL OVERVIEW OF ACYCLOVIR | |
| BE1026615B1 (fr) | Combinaison d’un inhibiteur du récepteur a2a et d'un agent anticancéreux | |
| JPH0616561A (ja) | 抗レトロウイルス剤 | |
| Van Genechten et al. | Case Report Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation | |
| EP4316518A1 (en) | Drug combination of toll-like receptor 7 agonist and anti-pd-l1 antibody | |
| HK40068610B (en) | Solid forms of a toll-like receptor modulator | |
| HK40068608A (en) | Solid forms of a toll-like receptor modulator |